Apr 2, 2026

Government investment will accelerate clinical development and strengthen Aspect’s advanced biomanufacturing capabilities for its bioengineered cellular medicines

VANCOUVER, BC – April 2, 2026 – Aspect Biosystems, a biotechnology company pioneering a novel category of regenerative medicine, today announced receiving a $79 million investment from the Government of Canada. The funding supports a $280 million, multi-year project to accelerate the advancement of Aspect’s pipeline of bioengineered cellular medicines for serious metabolic and endocrine diseases. The project will significantly enhance Aspect’s clinical development capabilities and strengthen the company’s vertically integrated platform for development and biomanufacturing of advanced cellular medicines. This builds upon a previously announced $200 million co-investment with the Government of Canada and the Province of British Columbia in 2024.

Aspect develops disease-modifying therapies designed to restore or supplement biological functions in the body. The company applies its full-stack platform, combining proprietary AI-powered bioprinting technology and hypoimmune cell engineering, to create scalable bioengineered cellular medicines.

“This investment from the Government of Canada is a powerful vote of confidence and adds to significant momentum at Aspect as we advance our bioengineered cellular medicines towards patient impact,” said Tamer Mohamed, CEO of Aspect Biosystems.

“Today’s announcement with Aspect Biosystems is an example of Canada’s leadership in scientific innovation and advanced biomanufacturing,” said the Honourable Mélanie Joly, Minister of Industry.

This partnership builds on recent momentum at Aspect, including entering a new phase of its partnership with Novo Nordisk earlier this year. It also follows a US$115 million Series B in 2025 and a $200 million co-investment with the Government of Canada and Province of British Columbia in 2024.

Source: Aspect Biosystems Press Release